Analyst Ratings for Mirum Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Mirum Pharmaceuticals (NASDAQ:MIRM) has received mostly bullish ratings from analysts in the last quarter, with 6 bullish, 2 somewhat bullish, and no bearish or indifferent ratings. The average 12-month price target for the company is $71.75, a decrease of 5.28% from the previous average of $75.75.
October 09, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals has received mostly bullish ratings from analysts, indicating a positive outlook for the company. However, the decrease in the average price target could suggest some caution.
The majority of analysts have given Mirum Pharmaceuticals a bullish rating, which typically indicates a positive outlook for the company's stock. However, the decrease in the average price target could suggest that analysts are becoming slightly less optimistic about the company's future performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100